These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8150755)

  • 41. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefepime: overview of activity in vitro and in vivo.
    Grassi GG; Grassi C
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():87-94. PubMed ID: 8150771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical evaluation of cefdinir 5% fine granules in pediatrics].
    Iwai N; Nakamura H; Taneda Y; Miyazu M; Kasai K; Watanabe Y
    Jpn J Antibiot; 1991 Oct; 44(10):1096-118. PubMed ID: 1762167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract].
    Quartieri F; Bolognesi S; Sconosciuto F
    Recenti Prog Med; 1994 Feb; 85(2):96-100. PubMed ID: 8184195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
    Tsuji M; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2544-51. PubMed ID: 8585742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evaluation of ceftazidime in the treatment of bacterial infections in eighty seriously ill patients.
    Walstad RA; Hellum KB; Svarva PL; Ingram PM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():131-7. PubMed ID: 6352614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cefpirome: efficacy in the treatment of urinary and respiratory tract infections and safety profile.
    Norrby SR
    Scand J Infect Dis Suppl; 1993; 91():41-50. PubMed ID: 8290902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of S-1108 in children].
    Meguro H; Mori A; Fujii R; Terashima I
    Jpn J Antibiot; 1993 Nov; 46(11):959-66. PubMed ID: 8309072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients.
    Jones ME; Karlowsky JA; Draghi DC; Thornsberry C; Sahm DF; Bradley JS
    Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):445-55. PubMed ID: 15156358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
    Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
    Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefepime clinical pharmacokinetics.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A
    Clin Pharmacokinet; 1993 Aug; 25(2):88-102. PubMed ID: 8403741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ceftazidime in clinical practice.
    Alestig K; Eilard T; Norrby R; Svensson R; Trollfors B; Brorson JE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():111-4. PubMed ID: 6225759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.
    Zervos M; Nelson M
    Antimicrob Agents Chemother; 1998 Apr; 42(4):729-33. PubMed ID: 9559773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Worldwide clinical experience with cefoperazone.
    Gerber AU; Craig WA
    Drugs; 1981; 22 Suppl 1():108-18. PubMed ID: 6456884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G; Cravarezza P
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.